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Interleukin 17 (IL-17) is one of the most potent inflam-
matory cytokines and has been strongly implicated in
inflammatory autoimmune disorders like rheumatoid
arthritis and multiple sclerosis. However, the role of
IL-17 in tumor progression is quite controversial and
the underlying mechanisms remain largely unknown.
Our group and others have recently reported the preva-
lence of IL-17 secreting cells in malignant gliomas and
studied the mechanism of their recruitment and
immune functions in the tumor milieu. Immunohisto-
chemistry and flow cytometry analysis of 14 tumor sam-
ples obtained from patients with malignant gliomas
revealed that a considerable population (2-19% of total
tumor cells) of all malignant gliomas expressed IL-17
receptor (IL-17R), with remarkable co-expression of the
glioma stem cell (GSC) markers CD133, Nestin, and
Sox-2. IL-17 enhanced the proliferation/self-renewal of
CD133+IL-17R+ GSCs and also enhanced the number of
GSC colonies in Matrigel® cultures. IL-17 also enhanced
the expression of mesenchymal stem cell markers, as
determined by qPCR analysis in GSC neurosphere cul-
tures. Moreover, IL-17 induced cytokine/chemokine (IL-
6, IL-8, interferon-g-inducible protein [IP-10], and
monocyte chemoattractant protein-1 [MCP-1]) secretion
in GSCs, which were differentially blocked by antibodies
to IL-17R and IL-6R. As determined by western blot
analysis, treatment of GSCs with IL-17 enhanced the
phosphorylation of signal transducer and activator of
transcription 3 (STAT3), nuclear factor -light-chain-
enhancer of activated B cells (NF-B), and glycogen
synthase kinase-3b (GSK-3b), while also enhancing
b-catenin activity. IL-17R-mediated secretion of IL-6
and IL-8 were significantly blocked by inhibitors of
STAT3 and NF-B. On the other hand, NF-B inhibitor
was more potent than STAT3 inhibitor in blocking
IL-17 induced MCP-1 secretion. Overall, our results
suggest that IL-17–IL-17R interaction in GSCs poten-
tially induces an autocrine/paracrine cytokine feedback
loop, which in turn may provide an important signaling
component for maintenance/self-renewal of GSCs via
constitutive activation of both NF-B and STAT3. This
study provides novel insight into IL-17R-mediated
inflammatory axis in glioma progression, which may
have significant impact on clinical interventions in
patients with malignant gliomas. Identification of IL-17R
as a functional molecular target on the surface of GSCs,
as presented in this study, could be a crucial first step
for larger studies towards developing unique immune/
therapeutic strategies aimed at either physical or functional
attenuation of the GSCs.
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